- Titre
- CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
- Créateurs - sans rôle
- Stephen J F Chong - Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), NUS Centre for Cancer Research (N2CR), NUS, Singapore, Republic of SingaporeRebecca Valentin - Department of Hematology, Rigshospitalet, Copenhagen, DenmarkJing Wang - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USAFen Zhu - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USAPrafulla C Gokhale - Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USABenjamin K Eschle - Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USAFilip Garbicz - Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAKartini Iskandar - Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), NUS Centre for Cancer Research (N2CR), NUS, Singapore, Republic of SingaporeTomasz Sewastianik - Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USABrienne C Y Toh - Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, N2CR, NUS, Singapore, SingaporeJohany Penailillo - Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAMarisa O Peluso - Surface Oncology, Inc., Cambridge, MA, USAJeremy Zhang - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USALiam Hackett - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USAMary C Collins - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USATimothy Z Lehmberg - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USAAmmar Adam - Surface Oncology, Inc., Cambridge, MA, USALi Zhang - Surface Oncology, Inc., Cambridge, MA, USACaroline M Armet - Surface Oncology, Inc., Cambridge, MA, USAMatthew Rausch - Surface Oncology, Inc., Cambridge, MA, USABenjamin H Lee - Surface Oncology, Inc., Cambridge, MA, USAPamela M Holland - Surface Oncology, Inc., Cambridge, MA, USAVito J Palombella - Surface Oncology, Inc., Cambridge, MA, USAAlison M Paterson - Surface Oncology, Inc., Cambridge, MA, USALi Ren Kong - Cancer Discovery and Regenerative Medicine Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Cancer Science Institute of Singapore, NUS, Singapore, SingaporeElisa Ten Hacken - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USAJennifer L Guerriero - Department of Surgery, Brigham and Women's Hospital, Boston, MA, USACharles Herbaux - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USACatherine J Wu - Dana-Farber Cancer InstituteWee Joo Chng - Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, N2CR, NUS, Singapore, SingaporeShazib Pervaiz - Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), NUS Centre for Cancer Research (N2CR), NUS, Singapore, Republic of SingaporeCarsten U Niemann - University of CopenhagenRuben D Carrasco - Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAMatthew S Davids - Dana-Farber Cancer Institute
- Détails de publication
- Journal of hematology and oncology
- Note de subvention
- NMRC/OFYIRG24JUL-0013 / National Medical Research Council R01CA266298 / NIH HHS NCI-P01CA206978 / NCI NIH HHS 2018/31/N/NZ5/03214 / Polish National Science Centre AcRF Tier 1, FY2024 / Ministry of Education - Singapore
- Identifiants
- 99159298309311
- Unité académique
- Institut de Génétique Humaine - IGH
- Langue
- English
- Type de ressource
- Journal article
Article de revue
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Journal of hematology and oncology
03/01/2026
PMID: 41484790
Indicateurs
1 Consultations de la notice